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Abstract
Background: Enhanced macromolecule biosynthesis is integral to growth and proliferation of cancer cells. Lipid
biosynthesis has been predicted to be an essential process in cancer cells. However, it is unclear which enzymes
within this pathway offer the best selectivity for cancer cells and could be suitable therapeutic targets.
Results: Using functional genomics, we identified stearoyl-CoA desaturase (SCD), an enzyme that controls synthesis
of unsaturated fatty acids, as essential in breast and prostate cancer cells. SCD inhibition altered cellular lipid
composition and impeded cell viability in the absence of exogenous lipids. SCD inhibition also altered cardiolipin
composition, leading to the release of cytochrome C and induction of apoptosis. Furthermore, SCD was required
for the generation of poly-unsaturated lipids in cancer cells grown in spheroid cultures, which resemble those
found in tumour tissue. We also found that SCD mRNA and protein expression is elevated in human breast cancers
and predicts poor survival in high-grade tumours. Finally, silencing of SCD in prostate orthografts efficiently blocked
tumour growth and significantly increased animal survival.
Conclusions: Our data implicate lipid desaturation as an essential process for cancer cell survival and suggest that
targeting SCD could efficiently limit tumour expansion, especially under the metabolically compromised conditions of
the tumour microenvironment.
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Background
Altered metabolism has now been established as a cen-
tral hallmark of oncogenic transformation [1]. Aberrant
activation of oncogenic signalling pathways and loss of
tumour suppressor function alters metabolic processes
in cancer cells to satisfy their increased energetic and
biosynthetic demand [2, 3]. Moreover, the reduced
availability of nutrients and oxygen in poorly vascu-
larised regions of solid tumours also affects the meta-
bolic activity of cancer cells [2, 4]. This metabolic
reprogramming supports cancer proliferation and sur-
vival but renders cancer cells highly susceptible to per-
turbations within the metabolic network [5].
Lipid metabolism is frequently altered in human can-
cer [6, 7]. While most normal adult tissues use dietary
lipids provided by the blood stream, many cancers show
increased rates of de novo fatty acid (FA) biosynthesis
[8]. The expression of most enzymes involved in FA bio-
synthesis is controlled by the sterol regulatory element
binding proteins (SREBPs) and can be induced down-
stream of the PI3-kinase/Akt/mTORC1 signalling pathway
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in cancer [9]. Consequently, de novo FA biosynthesis is
generally high in those tumour types that exhibit activating
mutations within this pathway, including breast and pros-
tate cancers [10, 11].
Several enzymes within the FA biosynthesis pathway
have been found to be essential for cancer cell growth and
survival and are currently pursued as targets for thera-
peutic development [6]. The potential selectivity of target-
ing lipid metabolism in cancer was also supported by a
systems biology study employing a genome scale model of
cancer metabolism that predicted specific dependence of
cancer cells on lipid metabolism enzymes [12]. This sug-
gests that targeting enzymes involved in these processes
should selectively interfere with the growth of cancer cells
without overt toxicity towards normal tissues.
Here, we show that cancer cells are highly dependent
on stearoyl-CoA desaturase (SCD), the enzyme that in-
troduces a double bond at the Δ9 position of newly syn-
thesised FAs. Loss of cell number was only detected
under lipid-depleted conditions and fully restored by ex-
ogenous mono-unsaturated FAs. Depletion of SCD
caused specific alterations in lipid composition, indicat-
ing reduced availability of unsaturated acyl chains for
the synthesis of phosphoglycerides and cardiolipins. In-
hibition of SCD led to the release of cytochrome C from
the mitochondria leading to the induction of apoptosis
and increased sensitivity towards cytotoxic drugs and in-
hibitors of mitochondrial respiratory complexes. The
sensitivity of cancer cells towards SCD inhibition was
greatly increased by spheroid culture, a condition that re-
capitulates nutrient and oxygen gradients found in tu-
mours. Expression of SCD is enhanced in human breast
cancer tissue and associated with high disease grade.
Finally, silencing of SCD resulted in efficient reduction of
tumour growth in prostate orthografts. Together, these re-
sults indicate that SCD is an important node in the metab-
olism of cancer cells and that inhibition of this enzyme
could provide a successful strategy for cancer treatment.
Methods
Antibodies and reagents
SCD inhibitors were purchased from Biovision and
Caymen chemicals. Anti-SCD antibodies (SCD11-A) were
from Alpha Diagnostics International and anti-Akt (9272),
anti-cytochrome C (11940S) and anti-PARP (9542) from
Cell Signalling. Hydrocortisone, EGF, Akt inhibitor (Akt V)
and staurosporin were from Calbiochem. Insulin, cholera
toxin, puromycin, doxycycline, paclitaxel and rotenone
were from Sigma-Aldrich and metformin from Tocris
Biosciences.
Cell culture
RWPE1 and LNCaP (clone FGC) were obtained from
the American Type Culture Collection. All other cell
lines were obtained from LRI Cell Services (CRUK LRI,
London, UK). All cell lines were authenticated using
STR profiling and used at low passage. RWPE1 cells
were grown in keratinocyte serum-free medium (Gibco)
supplemented with epidermal growth factor and bovine
pituitary extract (KGM). DU145, LNCaP and PC3 cells
were grown in RPMI supplemented with 2 mM L-
glutamine and penicillin/streptomycin. All breast cancer
cell lines were grown in DMEM/F12 supplemented with
serum, glutamine and penicillin/streptomycin. MCF10a
cells were grown in DMEM/F12 supplemented with 5 %
horse serum, 20 ng/ml EGF, 5 μg/ml hydrocortisone,
10 μg/ml insulin and 100 ng/ml cholera toxin.
RNA interference
Breast and prostate cancer cells were reverse-transfected
with 37.5 nM of Dharmacon siGENOME siRNA using
Lullaby reagent (Oz biosciences). After 24 h, culture
medium was replaced with either 10 % (full serum) or 1 %
(low serum) foetal calf serum (FCS) containing medium.
Additional supplementations were included for the experi-
ments indicated. After 72 h, cells were fixed in 80 % etha-
nol over night at −20 °C. Plates were subsequently stained
with DAPI (Sigma), and cell number was determined
using the ACUMEN X3 microplate cytometer.
Generation of doxycycline-inducible TetOnPLKO-shRNA
cell lines
shRNA sequences targeting SCD or non-targeting control
(NTC) were cloned into the TetOn-pLKO-puro lentiviral
vector [13]. Clone IDs for shRNAs are as follows: shSCD
#1 (TRCN0000056613) and shSCD #2 (TRCN0000056614).
Lentiviruses were produced by cotransfecting HEK293T
cells with lentiviral and packaging plasmids pCMVΔR8.91
and pMD.G. Supernatants were collected 72 h after trans-
fection, mixed with polybrene (8 μg/mL) and used to infect
cells. Cells were selected in medium containing puromycin
(2 μg/mL).
RNA extraction, reverse transcription, RT-qPCR
Total cell RNA was extracted using an RNeasy kit
(QIAGEN); 2 μg of RNA was utilized for first strand
cDNA synthesis with oligo-dT primers and Superscript II
Reverse Transcriptase (Invitrogen). RT-qPCR was per-
formed using SYBR® Green PCR Master Mix (Applied
Biosystems) and Quantitect primers (QIAGEN) on an
ABI Prism 7900 (Applied Biosystems). All reactions were
performed in duplicate, and relative mRNA expression
was calculated using the comparative Ct method after
normalization to the loading control B2M.
Protein analysis
Cells were lysed in Triton lysis buffer (1 % Triton X100,
50 mM Tris pH7.5, 300 mM NaCl, 1 mM EDTA, 1 mM
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DTT, 1 mM NaVO4, Protease-Inhibitor-Cocktail and
Phosphatase-Inhibitor-Cocktail (Roche)). Proteins were
separated on SDS-PAGE and blotted onto PVDF
membrane (Immobilon). Membranes were blocked
with 3 % bovine serum albumin (BSA) and incubated
with antibody solutions, and signals were detected
using ECL-reagent.
Lipidomic analysis
Stable isotope labelling was performed as in [14]. For
lipidomic analysis, lipids were extracted using a metha-
nol/chloroform extraction method and quantified by
LC-MS analysis on a Shimadzu IT-TOF LC/MS/MS sys-
tem. Accurate mass (with mass accuracy ~5 ppm) and
tandem MS were used for molecular species identifica-
tion and quantification. The identity of lipids was further
confirmed by reference to appropriate lipid standards.
Cell pellets were spiked with appropriate internal stan-
dards (for each sample, 100 ng 12:0/12:0/12:0-TG,
200 ng 12:0/12:0-DG, 100 ng 12:0-MG, 200 ng 17:0-FA,
100 ng C17-Cer, 50 ng C17-SG, 200 ng 14:0/14:0/14:0/
14:0-CL, 100 ng 12:0/12:0-PG, 200 ng 12:0/12:0-PE,
200 ng 12:0/12:0-PS, 400 ng 17:0/20:4-PI, 100 ng 12:0/
12:0-PA, 400 ng 12:0/12:0-PC, 100 ng 17:0-LPA, 100 ng
17:0-LPC, 100 ng 12:0-Cer1P, 100 ng C17-S1P, 200 ng
C17-SM and 50 ng C17-SPC) before extraction. The
samples were extracted using a modified Folch method:
first extraction with 4 ml chloroform:2 ml methanol:2 ml
0.88 % NaCl for each sample and second extraction of
upper phase with 3 ml of synthetic lower phase of
chloroform/methanol/0.88 % NaCl 2:1:1; the combined
lower phases of the lipid extract were dried using a
Thermo SpeedVac at room temperature under vacuum
and re-dissolved in 50 μl chloroform/methanol 1:1, of
which 7 μl was injected onto the column for LC-MS
analysis. For LC/MS/MS analysis, a Shimadzu IT-TOF
LC/MS/MS system hyphenated with a five-channel on-
line degasser, four-pump, column oven, and autosampler
with cooler Prominence HPLC (Shimadzu) was used. In
detail, lipid classes were separated on a normal phase
silica gel column (2.1 × 150mm, 4micro, MicoSolv Tech-
nology) using a hexane/dichloromethane/chloroform/
methanol/acetanitrile/water/ethylamine solvent gradient
based on the polarity of head group. Accurate mass
(with mass accuracy ~5 ppm) and tandem MS were used
for molecular species identification and quantification.
The identity of lipid was further confirmed by reference
to appropriate lipid standards. IT-TOF mass spectrom-
eter operation conditions: ESI interface voltage +4.5 kv
for positive ESI and −4 kv for negative ESI, heat block
temperature 230 °C, nebulising gas flow 1.4 L/min, and
CDL temperature 210 °C, with drying gas on at pressure
of 100 kPa. All solvents used for lipid extraction and
LC/MS/MS analysis were LC-MS grade from Fisher
Scientific. Lipid amounts were normalised by protein
concentrations of each sample.
Crystal violet staining
Cells were seeded on 12-well plates. After incubation,
cells were fixed with 70 % ethanol, stained with 0.01 %
crystal violet. For quantification, dye was extracted with
10 % acetic acid and OD was measured at 560 nm.
BrdU incorporation and apoptosis assays
Cells were labelled with BrdU for 1 h and analysed by
fluorescence-activated cell sorting (FACS). For detection
of apoptosis, cells were detached with trypsin and stained
with Annexin V-pacific blue and propidium iodide (PrI).
Relative proportion of viable cells and cells in early or late
apoptosis were determined by FACS analysis.
Oxygen consumption rates
Experiments were performed in a 96-well format using a
SeahorseBioscience XF96 Extracellular Flux Analyser
(Software Version 1.4) in assay medium supplemented
with 1 mM sodium pyruvate and 10 mM glucose, with
pH adjusted to 7.4. During the experiment, 1.264 μM
oligomycin A (Sigma), 0.4 μM FCCP (Sigma) and 1 μM
rotenone (Sigma) were injected. Oxygen consumption
rates (OCR) were normalised to cell number.
Spheroid growth assays
Cells were mixed with 2 % matrigel (BD Biosciences
356231) in culture medium and placed in 96-well ultra-
low attachment plates (Costar). Spheroid formation was
initiated by centrifugation at 850×g for 10 min. Fresh
growth medium was administered every 72 h. Spheroid
size was determined by automated imaging on an
inverted microscope (Axiovert 100 M, Carl Zeiss).
Spheroids were fixed in neutral buffered formalin (NBF),
suspended in 2 % agarose and paraffin embedded. Sec-
tions were incubated twice for 3 min in xylene, twice for
3 min in 100 % ethanol, twice for 2 min in 95 % indus-
trial methylated spirit (IMS), twice for 2 min in 70 %
IMS and rehydrated for 2 min in 50 % IMS before im-
munohistochemical analysis.
Immunohistochemistry
Tissue microarray (TMA) slides (BR1921a) were pur-
chased from US Biomax, Inc. (Rockville, MD, USA).
Antibody staining was performed as in [14]. Legal con-
sent was obtained by the company prior to collection of
material.
Comparative expression and survival analysis
Comparative expression analysis was performed using
Oncomine (Compendia Bioscience, Thermo Fisher
Scientific, Grand Island, NY, USA). Correlations between
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SCD expression and relapse-free survival in breast cancer
were calculated using the GOBO analysis tool [15].
Prostate orthograft tumour model
All the animal experiments conducted for this study
were carried out with ethical approval from University
of Glasgow under the revised Animal (Scientific Proce-
dures) Act 1986 and the EU Directive 2010/63/EU (PPL
30/3185). Animals were housed in individual ventilated
cages in a barrier facility proactive in environmental en-
richment. Balb/C-nude male mice were obtained from
Charles River Research Models and Services (UK). A
midline lower abdominal incision was made on mice
anesthetized by isoflurane inhalation. Using a 1-cc syr-
inge with a 27-gauge needle, 2 × 106 cells in 50 μl of
serum-free phenol red-free glutamine containing RPMI
were injected in one of the anterior prostate lobes. Mice
were gavaged daily (0.2 ml) with doxycycline (10 mg/ml)
starting at 10 days post-surgery or as indicated. Mice
were anaesthetised, intraperitoneally injected with Vivo-
Glo™ Luciferin (Promega) and imaged using an IVIS
Spectrum imaging system. Images were analysed using
the IVIS Living Image software. Ultrasound imaging was
carried out in three-dimensional (3D)-mode using Vevo®
3100 Imaging System (Visual Sonics).
Results
Targeted RNAi screen identifies SCD as an essential gene
in breast and prostate cancer cells
To identify genes selectively important for biomass accu-
mulation in cancer cells, while not impacting on energy
production in non-transformed cells, we employed an
unbiased screen of 66 genes involved in lipid metabolism.
These genes have been previously predicted to be essential
for cancer cells [12]. We have previously reported a func-
tional genomic screen in seven breast and three prostate
cancer cell lines, representative of different disease
subtypes (Additional file 1: Figure S1), and two non-
transformed cell lines from the same tissue (MCF10a
and RWPE1, respectively), which determined the effect
of gene silencing on the total cell number [14]. To ex-
pose the selective vulnerabilities of cancer cells likely to
be maintained in vivo [16–18], conditions of reduced
availability of serum-derived factors were included.
Comparison of the screen results obtained in full and
low serum revealed differential effects after silencing of
several genes, with the strongest difference observed
for SCD (Fig. 1a). Depletion of SCD in low serum
caused a significant reduction in cell number in nine
out of the ten cancer cell lines tested, while having little
or no effect on the two non-cancer cell lines, RWPE1
and MCF10A (Fig. 1b). These findings were confirmed
using independent siRNA sequences in four representa-
tive cancer cell lines. Depletion of SCD resulted in a
substantial reduction in cell number when cells were
grown in low serum (Fig. 1c). In contrast, depletion of
SCD in full serum only reduced cell numbers in T47D
cells while having little or no effect on the other three
lines (Fig. 1c). Low serum conditions did not influence
the cytotoxicity of depleting the G2/M cell cycle transi-
tion protein polo-like kinase 1 (PLK1) (Fig. 1c).
To confirm the reduction in cell number observed
after SCD silencing is due to loss of enzyme activity,
we used two structurally unrelated SCD inhibitors: 4-
(2-chlorophenoxy)-N-(3-(3-methylcarbamoyl)phenyl)pi-
peridine-1-carboxamide (SCDi I) and 3-[4-(2-chloro-
5-fluorophenoxy)-1-piperidinyl]-6-(5-methyl-1,3,4-oxa-
diazol-2-yl)-pyridazine (SCDi II). Treatment with SCDi
I reduced proliferation of breast and prostate cancer
cell lines grown in low serum in a dose-dependent
manner, while having almost no effect in full serum
(Fig. 1d), thus phenocopying the effect of gene silen-
cing. Similar results were obtained with SCDi II in
DU145 cells (Fig. 1e). Moreover, silencing of SCD
using two different shRNA hairpins also efficiently re-
duced cell numbers of DU145 cells grown in low
serum (Additional file 1: Figure S1b and c). Together,
these results implicate SCD in growth and survival of
cancer cells under serum-deprived conditions.
SCD expression is high in human prostate and breast
cancers and correlates with tumour grade
To investigate SCD expression in cancer, we queried
published datasets of human cancer. We found that
SCD was upregulated in ductal breast carcinoma in situ
and invasive ductal breast carcinoma (IDC—the most
common type of breast cancer) samples, compared to
normal tissue (Fig. 2a). Benign prostate hyperplasia,
prostate carcinoma and prostate adenocarcinoma sam-
ples also showed increased SCD expression (Fig. 2a). To
confirm the expression of SCD protein in breast cancer,
we performed immunohistochemical staining of a breast
cancer tissue microarray containing a total of 192 cores
representing different breast cancer subtypes. High SCD
expression was detected in approximately 20 % of IDCs,
while it was only detected at low levels in normal adja-
cent breast tissue (p = 0.0029) (Fig. 2b). In contrast, only
weak SCD staining was detected in invasive lobular car-
cinomas (ILCs), the second most common breast cancer
subtype (Fig. 2b). Increased expression of SCD in IDCs
compared to other breast cancer subtypes was also con-
firmed in a published mRNA dataset representing the six
most common breast cancer subtypes (Additional file 1:
Figure S1d). We also found that expression of SCD in-
creased with tumour grade (Fig. 2c and Additional file 1:
Figure S1e) and was higher in patients with low overall
survival (Additional file 1: Figure S1f). Finally, we found
that high SCD expression is predictive of poor relapse-free
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survival in breast cancer. This was particularly pro-
nounced in grade III tumours (Fig. 2d) and those express-
ing the PAM50 signature [19], indicative of the basal
subtype (Fig. 2f). Basal breast cancers are predominantly
of a high histological grade on detection (grade III) and
have an increased probability of metastatic progression
and formation of distal metastases [20]. Taken together,
these results demonstrate that SCD is expressed in breast
and prostate cancers and that high levels of SCD expres-
sion are indicative of advanced disease.
Low serum conditions alter the cellular lipid profile of
cancer cells
To examine whether the effect of SCD depletion in low
serum is a consequence of increased dependency on de
novo lipogenesis, DU145 prostate cancer cells were cul-
tured in media supplemented with stable isotopes of one
of the three main carbon sources for lipid biosynthesis,
13C-glucose, 13C-acetate or 13C-glutamine. Labelling of
intracellular palmitate was quantified using LC-MS-
based metabolomics. In full serum, labelled palmitate
derived from these precursors accounted only for a
minor fraction of the total pool, ranging from 5 to 10 %
(Fig. 3a). Culture in low serum conditions increased the
incorporation from all precursors (Fig. 3a), indicating
that serum depletion enhances de novo FA synthesis.
We next examined the composition of intracellular-
free FAs (FFAs) in DU145 cells grown under full and
low serum conditions. Strikingly, cells displayed high
amounts and relative abundance of mono-unsaturated
FFAs (Fig. 3b and Additional file 2: Figure S2a). In par-
ticular, the ratio between oleic acid (18:1) and stearic
acid (18:0) was significantly higher in the intracellular
FFA pool compared to serum FFAs (Additional file 2:
Figure S2b), suggesting that mono-unsaturated FFAs
are not derived from the serum FFA pool. However, it
is also possible that a proportion of intracellular
mono-unsaturated FFAs are derived from desaturated
phospholipids, such as lysophosphatidylcholine, as dem-
onstrated previously [21]. Interestingly, the levels of
mono-unsaturated FFAs were further increased when cells
were cultured in low serum (Fig. 3b), suggesting that the
high abundance of unsaturated intracellular FFAs in
cancer cells is a result of intrinsic desaturase activity
and is increased under conditions when extracellular
lipid supply is reduced and de novo FA synthesis is
activated.
SCD maintains fatty acid desaturation and viability in
cancer cells
To establish the consequences of SCD inhibition on cel-
lular lipid composition, we determined concentrations of
saturated, mono-unsaturated and poly-unsaturated FFAs
in DU145 prostate cancer cells following SCD inhibition
in low serum conditions (Additional file 3: Figure S3a).
As expected, levels of mono- and poly-unsaturated FFA
species were significantly reduced, while levels of satu-
rated FFAs were less affected (Fig. 4a and Additional file 3:
Figure S3b). Consequently, this caused an increase in the
relative proportion of saturated FFA in the total FFA pool
(Additional file 3: Figure S3c and d).
We next investigated the effect of restoring levels of
mono-unsaturated FFA on cellular lipid pools by provid-
ing cells with exogenous oleic acid at the same concen-
tration found in full medium. Efficient coupling of oleic
acid to BSA was confirmed by mass spectrometry
(Additional file 2: Figure S2c). Interestingly, addition of
oleic acid fully restored the amounts of mono- and
poly-unsaturated FFAs in the cells (Fig. 4a and Additional
file 3: Figure S3b) and reduced the relative proportion of
saturated FFAs in the cellular FFA pool (Additional file 3:
Figure S3d).
We also analysed acyl-chain length and composition
of membrane phosphoglycerides in cancer cells cul-
tured in full or low serum. Lipid species containing
mono-unsaturated acyl-chains showed a marked in-
crease in the amount in cells cultured in low serum
(Additional file 4: Figure S4), suggesting that newly syn-
thesised FAs contribute to the phosphoglyceride pool
under those conditions. Inhibition of SCD caused a
marked reduction in phosphatidylethanolamine (PE) con-
taining mono-unsaturated acyl-chains, with the major two
species, 36:1-PE and 36:2-PE, showing more than 50 %
reductions (Additional file 5: Figure S5a and b). This
(See figure on previous page.)
Fig. 1 SCD ablation is detrimental to breast and prostate cancer cell lines cultured in low serum. a Strictly standardised mean difference (SSMD)
calculated from cell numbers obtained in a functional genomic screen targeting lipid metabolism genes. Genes with the strongest differential
(Diff.) between full serum (10 % FCS, FS) and low serum (1 % FCS, LS) are shown. b Screen results for SCD RNAi across the panel of breast and
prostate cell lines. SSMD values below −2 indicate statistical significance. RWPE1 cells were cultured in KSFM. c Loss of cell number following
silencing of SCD or PLK1 in DU145, MDA-MB-468, PC3 and T47D cells cultured in full serum (FS) or low serum (LS) for 72 h. Cell numbers are
relative to non-targeting controls (RISC). Statistical comparisons were performed using Student t test (*p≤ 0.05). d Breast and prostate cancer cell
lines were treated with different doses of SCD inhibitor for 72 h in medium containing full (FS) or low (LS) serum. Cell numbers are relative to
untreated controls. Data represent the mean ± SEM of three independent biological replicates. Statistical comparisons were performed using
Student t test (*p ≤ 0.05). e DU145 cells were treated with increasing concentrations of two structurally distinct SCD inhibitors (SCDi I and SCDi II)
for 72 h in medium containing full (FS) or low (LS) serum. Cell number is relative to untreated controls. Data represent the mean ± SEM of three
independent biological replicates. Statistical comparisons were performed using Student t test (*p≤ 0.05)
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resulted in a relative increase of long-chain poly-
unsaturated PE species to the total pool (Additional
file 5: Figure S5c). Interestingly, re-addition of oleic
acid restored levels of mono-unsaturated PE (Additional
file 5: Figure S5b), while reducing the relative proportion
of some poly-unsaturated species (Additional file 5:
Figure S5c). Similar results were also obtained for
phosphatidylinositol (PI) and phosphatidylserine (PS)
(Additional file 6: Figure S6 and Additional file 7:
Figure S7, respectively).
To confirm that the loss in cell number after treat-
ment with siRNA and SCDi against SCD was indeed due
to reduced availability of mono-unsaturated FAs, we rea-
soned that supplementing cancer cells with oleic acid,
the enzymatic product of the SCD reaction, would res-
cue cell survival. Indeed, supplementation with BSA-
oleate completely restored cell viability in the presence
of SCD inhibitor (Fig. 4b) and prevented the reduction
in cell number following siRNA-mediated SCD silencing
(Fig. 4c). Importantly, addition of BSA-oleate did not
affect the viability of cells after silencing of PLK1, con-
firming the specificity of the assay (Fig. 4c). Moreover,
supplementation of oleic acid not only provided immedi-
ate relief from SCD inhibition but also supported long-
Fig. 2 SCD expression is increased in breast and prostate cancers and associated with poor survival. a Differential expression of SCD between
breast and prostate cancers and normal tissue found in different public datasets (Oncomine). b Immunohistochemical analysis of SCD in breast
cancer and normal adjacent tissue (NAT) samples from invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). SCD staining
intensity was classified as absent, low or high. Representative images of NAT and IDC samples indicating staining intensities. c Correlation of SCD
expression in IDC patient samples with tumour grade (Curtis dataset, Oncomine). d Kaplan Meier plots for relapse-free survival (RFS) stratified by
SCD expression in breast cancers of different grades. e Kaplan Meier plots for RFS stratified by SCD expression in patients with basal-like breast
cancers as determined by expression of the PAM50 signature
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term maintenance of viable cells in the presence of the
SCD inhibitor in low serum conditions (Fig. 4d). This
suggests that maintaining a pool of mono-unsaturated
FAs is essential for sustained cancer cell viability.
Inhibition of SCD alters cardiolipin composition and
sensitises cancer cells towards apoptosis
We next asked whether the reduction in cell number ob-
served after SCD inhibition is due to reduced prolifera-
tion or induction of cell death. BrdU labelling revealed
no change in cell proliferation after SCD inhibition
(Fig. 5a). In contrast, we observed an increase in
Annexin V-positive cells indicative of enhanced apop-
tosis (Fig. 5b). High levels of saturated FAs have been
shown to induce apoptosis in breast cancer cells due to
changes in cardiolipin (CL) turnover [22]. CLs are a class
of structurally unique phospholipids that are localised in
the inner membrane of mitochondria and have essential
roles in the function of this organelle. Acyl chains of CL
molecules are constantly remodelled, and their length
and degree of unsaturation have a large influence on the
function of CL-containing membranes [23].
We therefore investigated whether modulation of FA
availability from serum alters composition of CL mole-
cules in cancer cells. The major CL species in DU145
prostate cancer cells grown in full serum contain mainly
shorter acyl-chains with one or two double bonds each
(Additional file 8: Figure S8a). Cells cultured in low
serum contain significantly higher levels of mono- and
poly-unsaturated CL species (Fig. 5c), most prominently
70:4-CL and 72:4-CL (Additional file 8: Figure S8a),
indicating that reduced availability of exogenous lipids
and increased de novo lipid synthesis also affects the CL
pool. Moreover, inhibition of SCD caused a substantial
decrease in the levels of mono-unsaturated CL species,
while poly-unsaturated CLs, particularly those with
longer acyl-chains, were not affected (Fig. 5d and
Additional file 8: Figure S8b). Importantly, addition of
oleic acid restored the levels of mono-unsaturated CL
species (Fig. 5d).
As mentioned above, CLs are integral components of
mitochondrial inner membranes and control the release
of cytochrome C during apoptosis [24]. Indeed, reduced
CL synthesis in neonatal cardiomyocytes exposed to
palmitate has been shown to cause the release of cyto-
chrome C leading to apoptosis [25], indicating that CL
composition not only modulates the cellular response to
apoptotic stimuli but can also initiate cell death. We
therefore investigated the effect of SCD inhibition on
cytochrome C release and apoptosis in DU145 cells.
Treatment with SCD inhibitor caused the efficient re-
lease of cytochrome C into the cytoplasm in cells grown
in low serum (Fig. 5e). This was completely blocked by
supplementing the cells with exogenous oleic acid
(Fig. 5e), confirming that the release of cytochrome C is
caused by a lack of mono-unsaturated FAs. In contrast
to some previous reports [26–28], SCD inhibition did
not alter Akt phosphorylation, presumably because the
cells were cultured under reduced serum conditions. In-
stead, we noticed that treatment with oleic acid induced
a small increase in Akt phosphorylation (Fig. 5e). How-
ever, pre-treatment with an Akt inhibitor did not block
Fig. 3 Low serum conditions induce de novo lipogenesis and alter the composition of cellular free fatty acids. a Incorporation of 13C-carbon from
glucose, glutamine or acetate in full (FS) or low (LS) serum in DU145 cells. b Quantitative lipid profiling of FFA content of DU145 cells grown in
full (FS) or low (LS) serum for 48 h using LC-MS/MS. Data represent the mean ± SEM of three biologically independent replicates. Statistical
comparisons were performed using Student t test (*p ≤ 0.05)
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the ability of oleic acid to prevent cytochrome C release
(Fig. 5f ), indicating that oleic acid supports cell survival
by restoring cellular lipid composition rather than al-
tering Akt signalling. Moreover, induction of PARP
cleavage in response to SCD inhibition or silencing was
also completely blocked by oleic acid (Fig. 5g, h).
As cytochrome C is an integral component of the elec-
tron transport chain (ETC.), we also analysed the effect
of SCD inhibition on oxygen consumption in cancer
cells. Treatment of DU145 or MDA-MB-468 cells with
SCD inhibitor in low serum not only reduced the basal
OCR but also lowered maximal respiration in the
uncoupled state, confirming that the activity of the ETC.
is impaired in these cells (Fig. 5i). Moreover, SCD inhib-
ition sensitised cancer cells towards metformin and rote-
none, two inhibitors of complex I of the respiratory
chain (Fig. 5j, k). We also investigated whether attenu-
ation of SCD activity also increases the sensitivity of
cancer cells towards drugs that induce apoptosis via the
mitochondrial death pathway. While treatment with low
doses of SCD inhibitor alone had little effect on cell via-
bility, we found that it enhanced the toxicity of paclitaxel
and staurosporine (Fig. 5l, m). Taken together, these re-
sults suggest that SCD inhibition causes alterations in
the composition of lipids that are crucial for the function
of the inner mitochondrial membrane and that altered
lipid desaturation can enhance the susceptibility of can-
cer cells towards chemotherapeutic drugs and metabolic
inhibitors.
Spheroid cultures exhibit tumour-like lipid composition
and depend on SCD activity
Many biosynthetic processes are modulated by the
tumour microenvironment, which determines the avail-
ability of nutrient and oxygen for metabolic reactions.
As the SCD reaction requires molecular oxygen, it is
likely that lipid desaturation is affected by tumour hyp-
oxia. To explore the effect of different environmental
conditions on the saturation levels of cellular lipid spe-
cies, we used BT474, a highly tumourigenic HER2- and
ER-positive breast cancer cell line, which readily forms
xenograft tumours. These cells were cultured under nor-
moxic (20 % O2) and hypoxic (0.1 % O2) conditions as
two-dimensional (2D) cultures and subjected to lipid
analysis. We mainly focused on diacylglycerol (DG) and
phosphatidylcholine (PC), two lipid classes that show
rapid turnover of their acyl chains [24] and should there-
fore reflect the availability of different FA species for
membrane synthesis in these cells. Surprisingly, altering
oxygen concentrations only led to a small increase in
saturated lipids and only a marginal reduction in mono-
and poly-unsaturated DG and PC species (Fig. 6a and
Additional file 9: Figure S9a and b). This indicates that
these culture conditions alone do not compromise the
availability of unsaturated FAs for lipid synthesis. We
next analysed lipids extracted from BT474 cells grown
as orthotopic xenograft tumours. Compared to cells cul-
tured in 2D, tumours showed a marked increase in the
relative amounts of DG and PC species containing two
or more double bonds (Fig. 6a and Additional file 9:
Figure S9a and b), suggesting that the in vivo environment
induces synthesis and/or uptake of unsaturated lipids.
Cancer cells can be grown as multi-layered 3D spher-
oids. These structures recreate the nutrient and oxygen
gradients that cancer cells are exposed to within a grow-
ing tumour. We found that T47D cells grown as tumour
spheroids show a similar increase in poly-unsaturated
DG species as found in tumours (Fig. 6b and Additional
file 9: Figure S9c). Moreover, increased levels of several
mono-unsaturated lipid species, most prominently PI
and lysophosphatidic acid (LPA), were also detected
(Fig. 6c). To examine the effect of SCD ablation on lipid
composition in these conditions, we used DU145 cells
expressing inducible shRNA hairpins targeting SCD to
generate spheroids. These were cultured in full medium,
and gene silencing was activated with doxycycline. As
can be seen from the data shown in Fig. 6d, depletion of
SCD caused a marked decrease in the relative amount
of mono- and poly-unsaturated FFA species (Fig. 6d
and Additional file 10: Figure S10a). Furthermore, the
(See figure on previous page.)
Fig. 4 SCD maintains fatty acid desaturation to support viability of cancer cells. a DU145 cells were treated with SCD inhibitors (100 nM) or
solvent (DMSO) for 48 h in medium with low serum or supplemented with BSA or BSA-coupled oleic acid (BSA-oleate). Quantitative lipid profiling
of free fatty acids (FFA) content was performed by LC-MS/MS. Concentrations of saturated, mono-unsaturated and poly-unsaturated FFA are
displayed. Data represent the mean ± SEM of three biologically independent replicates. Statistical comparisons were performed using Student t
test (*p≤ 0.05). b DU145 cells were treated with increasing concentrations of SCD inhibitor for 72 h in medium containing full (FS) or low serum
(LS) or medium supplemented with BSA or BSA-oleate. Cell numbers are normalised to solvent treated controls. Statistical comparisons were
performed using Student t test (*p≤ 0.05). c DU145 cells were transfected with siRNA targeting SCD (siSCD), PLK1 (siPLK1) or non-targeting
controls (siCtrl). Cells were cultured for 72 h in medium containing full (FS) or low serum (LS) or medium supplemented with BSA or BSA-oleate.
Cell numbers are displayed relative to untreated siCtrl transfected cells. Data represent the mean ± SEM of two biologically independent
experiments with two replicates each. Statistical comparisons were performed using Student t test (*p≤ 0.05). d DU145, PC3 and MDA-MB-468
cells were treated with SCD inhibitor (SCDi I) or solvent (DMSO) under full (FS) or low (LS) serum conditions for 10 days. Cells were stained using
crystal violet and quantified. Data represent mean ± SEM of two biologically independent experiments. Statistical comparisons were performed
using Student t test (*p≤ 0.05)
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poly-unsaturated DG population, which was selectively
upregulated in tumours (see Fig. 6a), was reduced when
SCD was ablated (Fig. 6e and Additional file 10: Figure
S10b). This was accompanied by a substantial reduction
in spheroid size despite the presence of serum in the
culture medium (Fig. 6f). A similar reduction on spheroid
size was observed in MDA-MB-468 breast cancer cells fol-
lowing inhibition of SCD activity (Fig. 6g). Interestingly,
this activity was seen at a concentration of the drug that
was ineffective at inhibiting cell growth in 2D cultures in
full serum (see Fig. 1d), suggesting that spheroid culture
sensitises cancer cells towards SCD inhibition. These data
confirm that SCD activity is essential to maintain levels of
mono-unsaturated FAs in cancer cells exposed to the
compromised metabolic environment created by 3D cul-
ture and that these FAs are rate limiting for cell growth
under these conditions.
SCD is essential for orthotopic growth of prostate cancers
Having shown that SCD is important to control lipid
provision under conditions that resemble the metabolic
microenvironment of tumours, we next investigated
whether SCD expression is also essential for tumour
growth. We implanted DU145 prostate cancer cells ex-
pressing inducible shRNAs targeting SCD orthotopically
into the prostates of immunocompromised mice (nu/nu).
Induction of gene silencing was induced with doxycycline.
In one cohort, treatment was started 10 days after im-
plantation when tumours were already detectable by bio-
luminescence imaging (early). In order to investigate the
effect of SCD inhibition on established tumours, a second
cohort was treated with doxycycline starting at day 47
post-implantation (late). Tumour growth was monitored
over time, and mice were culled upon reaching the hu-
mane endpoint.
In the early treatment regimen, SCD ablation resulted
in a substantial attenuation in tumour growth, while tu-
mours in the untreated cohort, or the doxycycline-
treated mice implanted with DU145 cells expressing
non-targeting controls, continued to expand (Fig. 7a).
Indeed, SCD silenced tumours were almost undetect-
able 25 days after doxycyline treatment was initiated
(Fig. 7b). This difference in tumour size was confirmed
by 3D sonographic imaging (Fig. 7c and Additional file
11: Movies S1–S8). Furthermore, SCD ablation also re-
sulted in a significant increase in the life span of treated
mice (Fig. 7d). In the late treatment group, SCD
ablation did not have a major impact on tumour size as
determined by bioluminescence imaging (data not
shown). Nevertheless, SCD ablation still resulted in a
discernable increase in survival compared to the un-
treated cohort (Fig. 7d). These results show that SCD is
essential for the growth and survival of cancer cells ex-
posed to the metabolic constraints of their native tissue
environment.
In summary, our results demonstrate that SCD is an
important enzyme to support the enhanced de novo
lipid synthesis and desaturation in cancer cells under
conditions where exogenous lipids are limiting. SCD
controls the production of lipid species that are import-
ant for cell viability and determine the sensitivity of can-
cer cells towards chemotherapeutic agents. Finally, SCD
is essential for tumour cell growth within the metabolic
restraints of the tissue that they arise in.
(See figure on previous page.)
Fig. 5 SCD inhibition alters cellular cardiolipin composition leading to cytochrome C release and sensitisation towards apoptosis. a DU145 cells
were treated with different concentrations of SCD inhibitor (SCDi II) and proliferation was determined by BrdU labelling. b Cells treated as in a
were used to determine apoptosis using Annexin V staining. Data represent mean ± SEM of three independent biological replicates. Statistical
comparisons were performed using Student t test (*p ≤ 0.05). c Quantitative lipid profiling of cardiolipin (CL) content of DU145 cells grown
for 48 h in medium containing full (FS) or low (LS) serum using LC-MS/MS. Concentrations of mono-unsaturated (≤4 double bonds) and
poly-unsaturated (>4 double bonds) CL species are displayed. Data represent the mean ± SEM of three independent biological replicates.
Statistical comparisons were performed using Student t test (***p≤ 0.001). d DU145 cells were treated with SCD inhibitors (100 nM) or solvent
(DMSO) for 48 h in medium containing low serum or medium supplemented with BSA or BSA-coupled oleic acid (BSA-Oleate). Quantitative lipid
profiling of CL content was determined using LC-MS/MS. Concentrations of mono- and poly-unsaturated CL species are displayed. Data represent
the mean ± SEM of three independent biological replicates. Statistical comparisons were performed using Student t tests (*p≤ 0.05). e DU145 cells
were treated with SCD inhibitor (SCDi I) or solvent (DMSO) for 48 h in medium containing low serum or medium supplemented with BSA or
BSA-oleate. Cells were lysed by digitonin, and the presence of cytoplasmic cytochrome C was determined. UV treatment was used as positive
control. Vinculin is shown as loading control. Levels of phosphorylated Akt (S473) and total Akt were detected in total lysates. f DU145 cells were
treated as in e but 3 μM of Akt inhibitor was added prior to addition of BSA-oleate. Cytoplasmic cytochrome C was detected in digitonin
lysates. g DU145 cells were treated with SCD inhibitor (SCDi I) or solvent (DMSO) in medium containing full (FS) or low (LS) serum or medium
supplemented with BSA or BSA-oleate. The presence of full-length and cleaved (cl.) PARP was determined. Actin is shown as loading control. h
DU145 cells were transfected with siRNA targeting SCD (siSCD) or non-targeting controls (siCtrl) and cultured as in e. The presence of full-length
and cleaved (cl.) PARP was determined. Actin is shown as loading control. i DU145 or MDA-MB-468 cells were treated with SCD inhibitor
(100 nM) for 48 h, and oxygen consumption rate (OCR) before and after addition of oligomycin, FCCP and rotenone was determined using a
Seahorse Bioanalyzer. j–m DU145 cells were treated with the indicated doses of SCD inhibitor (SCDi II) either alone or in combination with
different doses of metformin (Metf, j), rotenone (RN, k), paclitaxel (PTX, l) or staurosporin (STP, m) for 72 h in medium containing low serum. Cell
viability was determined by crystal violet staining. Data represent the mean ± SEM of three independent biological replicates. Statistical
comparisons were performed using Student t tests (*p≤ 0.05, **p≤ 0.01 compared to SCDi alone; #p≤ 0.05, ##p≤ 0.01 compared to no SCDi)
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Discussion
Increased lipid biosynthesis is an important feature of
cancer cells [6, 7, 29]. Inhibitors of fatty acid synthase
(FASN) have so far shown limited therapeutic promise
due to systemic toxicity [30]. Defining the exact contri-
bution of lipid metabolism enzymes to cancer cell
growth and survival is crucial to identify potential new
therapeutic targets.
In this study, we analysed the response of breast and
prostate cancer cell lines to the depletion of SCD, a rate-
limiting enzyme for the production of mono-unsaturated
fatty acids. We found that silencing of SCD reduced pro-
liferation in almost all cancer cells lines studied without
affecting the viability of non-malignant epithelial cell
lines derived from the same tissues. In contrast to previ-
ous reports [31], we did not observe a cell cycle arrest in
response to SCD inhibition. This could be because the
cells were already cycling slower due to the reduced
availability of serum-derived growth factors. Neverthe-
less, the strong and selective dependence of cancer cells
on lipid desaturation observed here is in agreement with
previous reports [31, 32]. It is possible that increased
lipid desaturation maintains cellular functions that are
selectively important in cancer cells. Indeed, lipid desat-
uration was shown to prevent engagement of the un-
folded protein response in cancer cells due to their
increased rates of protein synthesis [17, 18, 33].
SCD has been previously linked to cancer cell prolifer-
ation and survival [34, 35]. Increased expression of SCD
has been found in several cancer types, including pros-
tate [27, 36], liver [37], kidney [38] and breast cancer
[39]. Inhibition of SCD by expression of antisense RNA
reduced tumour formation in human lung adenocarcin-
oma cancer cells [26] while pharmacological inhibition
of SCD was effective in blocking the growth of gastric
and colon cancer cells [32, 36]. SCD also promotes pro-
liferation and disease progression in prostate cancer by
affecting cellular signaling cascades and modulating an-
drogen receptor transactivation [27, 40]. Furthermore, it
has been shown that breast cancers contain higher
proportions of saturated and mono-unsaturated lipid
species, indicative of increased lipid synthesis and desat-
uration rather than uptake of dietary lipids [41]. The
same study also found reduced viability after SCD silen-
cing in breast cancer cells [41], confirming the import-
ance of this enzyme for cancer metabolism. Finally,
altered serum lipids also offer diagnostic opportunities
as reduced levels of triacylglycerides containing oleic
acid were found to be indicative of prolonged survival in
breast cancer patients after neoadjuvant treatment [42].
Our study provides additional evidence for the import-
ant role of SCD in cancer. We found that SCD is overex-
pressed in breast and prostate cancers compared to
normal tissues. In breast cancer, high levels of SCD ex-
pression were confined to invasive ductal breast car-
cinomas but absent in invasive lobular carcinomas,
providing important subtype specification. Moreover,
SCD expression correlated with tumour grade and was
indicative of disease relapse. SCD expression also de-
termined reduced progression-free survival of high-
grade tumours and those stratified by the PAM50 gene
expression signature, which defines basal-like aggres-
sive disease that presently has limited therapeutic op-
tions [19]. In keeping with this finding, three out of the
four triple negative breast cancer cell lines used in this
study showed high sensitivity towards SCD depletion.
Our study further demonstrates that the dependence
of cancer cells on SCD is strongly determined by the
availability of exogenous lipids. Lipid deprivation in-
creased de novo lipid biosynthesis and enhanced the
contribution of mono-unsaturated FAs to the cellular
lipid pool. We also confirmed that the effect of SCD si-
lencing on cancer cell viability was due to inhibition of
enzymatic activity, as two structurally unrelated inhibi-
tors of SCD activity showed comparable efficacy in
reducing proliferation and survival in cancer cells. Both
inhibitors reduced the levels of mono- and poly-
unsaturated FA species and increased the relative abun-
dance of saturated forms. This shift towards higher
saturation could also be observed in the acyl chains of
several membrane phosphoglycerides, indicating that SCD
inhibition alters the composition of important cellular
(See figure on previous page.)
Fig. 6 Spheroid culture reveals metabolic dependency of cancer cells on lipid desaturation. a BT474 cells were cultured in normoxia (20 % O2) or
hypoxia (0.1 % O2) for 48 h before lipids were extracted and used to determine the relative amount of diacylglycerol (DG) and phosphatidylcholine
(PC) species by LC-MS/MS. Archival tissue from six individual orthotopic xenograft tumours of BT474 cells [14] was also analysed. Statistical comparisons
were performed using Student t tests (*p≤ 0.05). b Lipids were extracted from T47D cells grown in adherent cultures (2D) or as tumour spheroids.
Relative distribution of unsaturated and mono- or poly-unsaturated DAG species are shown. c Selected mono-unsaturated lipid species from T47D cells
grown in 2D or as tumour spheroids. d, e DU145 cells expressing inducible shRNAs targeting SCD (shSCD #2) or scrambled control (shNTC) were
grown as spheroids in the presence of solvent (EtOH) or 0.5 μg/ml doxycycline (DOX). Spheroids taken at day 9 were subjected to quantitative lipid
profiling and relative amounts of free fatty acids (FFA, d) and diacylglycerol species (DAG, e) were determined. Data represent the mean ± SEM of three
independent biological replicates. Statistical comparisons were performed using Student t tests (*p≤ 0.05). f Spheroid size was determined at the
indicated times. Spheroids taken at day 9 were fixed and subjected to immunohistochemical staining of SCD and H&E staining. g Spheroids of
MDA-MB-468 cells were treated with 100 nM of SCD inhibitors for 4 days and spheroid size was determined. Statistical comparisons were performed
using Student t test (*p≤ 0.05)
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lipid species. However, the amounts of some phosphogly-
ceride species containing long-chain poly-unsaturated FAs
were increased following SCD inhibition, suggesting that
cells can remodel existing lipid pools or selectively take up
certain lipid species when desaturation is blocked. Indeed,
it has been shown that the selective uptake of unsaturated
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Fig. 7 SCD is essential for orthotopic tumour growth of prostate cancer cells. a DU145 cells expressing inducible shRNAs targeting SCD (shSCD #2) or
scrambled control (shNTC) were injected orthotopically into the frontal lobe of the prostate of immunocompromised mice (nu/nu). Gene silencing was
induced 10 days post-implantation by treatment with doxycycline (DOX). Tumour growth was followed using intravital bioluminescence imaging of
luciferase-positive cancer cells. Data represent mean bioluminescence ± SEM of eight mice per treatment group. Statistical comparisons were performed
using Student t-tests (***p≤ 0.0001). b Images of bioluminescence in mice at day 25 after initiation of doxycycline treatment. c Representative images of
tumours detected by 3D ultrasound imaging 27 days after initiation of doxycycline treatment. d Survival curves of mice orthotopically implanted with
prostate cancer cells and treated with doxycycline from day 10 onwards (early, red line) or day 47 onwards (late, blue line) compared to controls. Statistical
comparisons were performed using the log-rank (Mantel-Cox) test (**p≤ 0.001). e Schematic representation of the vulnerability of cancer cells towards
inhibition of FA desaturation under the metabolically compromised conditions of the tumour microenvironment. Our data suggest that tumour cells are
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relative accumulation of saturated FAs and disturbs CL compositions resulting in release of cytochrome C, reduced mitochondrial activity, enhanced
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lyso-phospholipids is induced by hypoxia and in Ras-
transformed cells [21].
Interestingly, we found that re-addition of oleic acid
restored most of the alterations in lipid composition in-
duced by SCD inhibition, confirming that this mono-
unsaturated FA is indeed rate-limiting for the generation
of a large part of the cellular lipid spectrum when ex-
ogenous lipids are scarce. Addition of oleic acid also pre-
vented the loss of cell viability in response to SCD
silencing or inhibition. This effect was maintained over
several days, providing sufficient lipid substrate for
membrane biosynthesis during this time. Of particular
importance in this context is the continuous functionality
of the inner mitochondrial membrane, which contains a
high proportion of cardiolipins (CL). The degree of de-
saturation determines the function of this highly spe-
cialized lipid class, and the acyl chains in CL molecules
undergo constant remodeling [23]. The composition of
different CL molecules within the inner mitochondrial
membrane can modulate the activity of ETC. com-
plexes [24]. Moreover, the acyl chains of CL molecules
interact with cytochrome c, thereby affecting both res-
piration and apoptosis [43].
We found that inhibition of SCD reduced levels of
mono-unsaturated CL species, with a specific reduction
in mono-unsaturated species. This was accompanied by
the release of cytochrome C and induction of apoptosis.
Sub-lethal doses of SCD inhibitor also increased the sen-
sitivity of cancer cells towards chemotherapeutic agents
and inhibitors of mitochondrial respiratory complexes.
This is in agreement with a recent study showing that
betulinic acid alters the saturation of CL species, causing
mitochondrial damage and cytochrome C release, most
likely through inhibition of SCD function [44]. It is also
possible that the reported activation of AMP-activated
protein kinase (AMPK) by SCD [45] could involve inhib-
ition of mitochondrial activity by altering cellular CL
composition.
We also observed that different culture conditions
have substantial effects on lipid composition. Human
cancer cells grown as orthotopic tumours exhibited spe-
cific lipid profiles that were characterised by high levels
of mono- and poly-unsaturated lipid species. These lipid
profiles were also detected in tumour spheroids, an ex-
perimental system that recreates the oxygen and nutri-
ent gradients observed in tumors. Silencing of SCD
reduced the ability of cancer cells to grow as spheroids,
indicating that these conditions restrict the access to
exogenous lipids making cancer cells dependent on
SCD function. Cells within metabolically restricted
hypoxic areas of human tumors frequently show ther-
apy resistance and increased stem cell capabilities
[46], making the selective targeting of this niche a
therapeutic priority.
Most importantly, we found that depletion of SCD ef-
ficiently blocked the ability of prostate cancer cells to
grow as orthotopic tumour xenografts, resulting in re-
duced tumour volume and prolonged survival of the
host. This effect was also observed when SCD silencing
was initiated after the tumours had already grown to a
substantial size, indicating that targeting SCD could offer
treatment opportunities in established cancer. It should
be noted that the RNAi strategy used here selectively
targets SCD only in cancer cells. This excludes potential
effects on desaturase activity in cells of the tumour
stroma or global alterations in the lipid metabolism of
the host, which can contribute to tumour inhibition by
systemic SCD inhibition.
Conclusions
This study demonstrates that SCD is deregulated in human
breast and prostate cancers and essential for cancer cell
survival and tumour growth. Inhibition of SCD altered
cellular lipid composition, leading to a distinct reduction in
particular lipid species that depend on the availability of
mono-unsaturated FAs. This phenotype was only observed
under conditions when exogenous lipid sources were
limited. The functional consequences of deregulated lipid
metabolism in response to SCD inhibition included
mitochondrial dysfunction, release of cytochrome C and
induction of apoptosis, confirming the important role of
fatty acid desaturation for essential cellular processes.
Taken together, our results highlight the importance of
SCD for lipid provision in cancer cells under the metabolic-
ally compromised conditions that are likely to be encoun-
tered within the tumour microenvironment (Fig. 7e). We
conclude that synthesis of mono-unsaturated FAs by SCD
represents a metabolic bottleneck of lipid biosynthesis and
thus provides a suitable target for therapeutic development.
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